“I’m exhausted, however completely satisfied,” says Melissa Moore, who led Moderna’s platform staff throughout the firm’s profitable effort to develop a vaccine for COVID-19, acquiring FDA emergency use authorization on December 18—lower than a 12 months after getting the genetic sequence for novel coronavirus. Whereas most vaccines stimulate an immune response by “exhibiting” the immune system a model of a ...